Amy Abernethy - 17 Dec 2021 Form 4 Insider Report for EQRx, Inc. (EQRX)

Role
Director
Signature
/s/ William Collins, Attorney-in-Fact
Issuer symbol
EQRX
Transactions as of
17 Dec 2021
Transactions value $
$0
Form type
4
Filing time
21 Dec 2021, 05:30:23 UTC
Previous filing
03 Aug 2021
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EQRX Class A Common Stock Options Exercise +200,000 200,000 17 Dec 2021 Direct F1
transaction EQRX Class A Common Stock Other -200,000 -100% 0 17 Dec 2021 Direct F2
transaction EQRX Common Stock Other +200,000 200,000 17 Dec 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EQRX Class B Common Stock Options Exercise -200,000 -100% 0 17 Dec 2021 Class A Common Stock 200,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion").
F2 Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock.

Remarks:

Exhibit 24 - Power of Attorney